L3VLUP
ProSign in

MNKD · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MNKDLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MNKD
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterMNKDLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 20211 holders, $5.5m24 holders, $23.0bn
Q2 20211 holders, $13m24 holders, $27.8bn
Q3 20212 holders, $6.4m31 holders, $29.9bn
Q4 20211 holders, $5.9m31 holders, $34.7bn
Q1 20223 holders, $6.0m24 holders, $35.3bn
Q2 20222 holders, $11m33 holders, $42.7bn
Q3 20223 holders, $17m31 holders, $43.4bn
Q4 20222 holders, $19m31 holders, $46.6bn
Q1 20231 holders, $7.5m33 holders, $44.3bn
Q2 20231 holders, $2.0m37 holders, $59.6bn
Q3 2023none listed holders, n.a.44 holders, $67.6bn
Q4 2023none listed holders, n.a.45 holders, $73.6bn
Q1 2024none listed holders, n.a.41 holders, $95.3bn
Q2 2024none listed holders, n.a.43 holders, $110bn
Q3 20243 holders, $25m45 holders, $107bn
Q4 20245 holders, $72m46 holders, $93.9bn
Q1 20252 holders, $23m42 holders, $98.4bn
Q2 20252 holders, $13m43 holders, $93.2bn
Q3 2025none listed holders, n.a.39 holders, $86.7bn
Q4 2025none listed holders, n.a.41 holders, $123bn
Q1 2026none listed holders, n.a.39 holders, $106bn
Q2 2026none listed holders, n.a.44 holders, $132bn
MNKD

Mannkind Corp

Holders
2
Reported value
$23m
Buyers
2
Sellers
0

Breadth +2 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
42
Reported value
$98.4bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MNKD (1)

ExodusPoint Capital Management LP

Only LLY (41)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Egerton Capital UK LLP, Eisler Capital Management Ltd, Element Capital Management LLC, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Lone Pine Capital LLC, and 16 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →